Cornell University’s Red Bear Angels Invests in Celestial Therapeutics

Celestial Therapeutics Inc. is proud to announce that it has secured an investment from a prominent angel group affiliated with Cornell University, Red Bear Angels (RBA). The investment will be used to advance Celestial’s novel next generation mRNA vaccines and anti-viral/anti-inflammatory therapeutic programs. 

RBA is related to Cornell University whose members consist of prominent Cornell alumni. RBA has invested in a number of startups including in biotech, technology and healthcare projects.

“RBA’s support of Celestial and its investment in the company will enable us to accelerate our research and development” Celestial’s CEO, Dr. Ajay Gupta said.

“We are excited to invest in Celestial and are impressed with what they have accomplished so far and look forward to their continued success to advance their novel vaccines and therapeutics to bring them to the clinic and to patients hands.” RBA’s CEO, Sam Sezak said.

About Celestial Therapeutics

Celestial Therapeutics is developing novel and ground breaking mRNA vaccines and therapeutics to treat, prevent and cure infectious diseases, inflammatory conditions and cancers. Celestial’s mission is to effectively treat respiratory viral infections & inflammation, cancers, prevent pandemics, save lives, reduce healthcare costs and address unmet medical needs for millions of patients worldwide. Founded in 2019, Celestial has rapidly built a diverse portfolio based on innovative innate immunity platform technologies. Celestial’s lead therapeutic platform, CT-02 is a first-in-class of a new class of broad spectrum anti-infective/anti-inflammatory drugs initially being developed for the treatment of Respiratory Syncytial Virus and Allergic Asthma. Celestial is also developing the next generation and truly disruptive mRNA vaccine and therapeutics platform. The Celestial team consists of industry veterans and prominent academicians with a proven track record.